Table II.
Association of ZNF382 promoter methylation with clinicopathological characteristics in the 105 pediatric AML samples.
| Clinical variables | No. of patients | ZNF382 methylation (n) | P-value | |
|---|---|---|---|---|
|
| ||||
| Negative | Positive | |||
| Gender | ||||
| Male | 42 | 30 | 12 | 0.719 |
| Female | 63 | 47 | 16 | |
| Age (years) | ||||
| <6 | 60 | 42 | 18 | 0.372 |
| ≥6 | 45 | 35 | 10 | |
| Leukocytes (/μl) | ||||
| >10,000 | 61 | 43 | 18 | 0.438 |
| ≤10,000 | 44 | 34 | 10 | |
| FAB score | ||||
| M1-M6 | 93 | 71 | 22 | 0.052 |
| M7 | 12 | 6 | 6 | |
| Cytogenetics | ||||
| Favorable | 50 | 36 | 14 | 0.955 |
| Intermediate | 27 | 20 | 7 | |
| Unfavorable | 28 | 21 | 7 | |
| MRD | ||||
| <0.25% | 49 | 41 | 8 | 0.025 |
| ≥0.25% | 56 | 36 | 20 | |
ZNF382, zinc finger protein 382; AML, acute myeloid leukemia; FAB, French-American-British classification; MRD, minimal residual disease.